Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

With the rising popularity of telehealth providers offering GLP-1 medications like Ozempic, the terminology can get confusing ...

Sanofi insisted the sale would help Opella expand by bringing in a partner willing to invest in a market that has more in common with the consumer goods market than pure pharmaceutical drugs.

Sanofi India net profit down 46% in quarter ended September 30: Our Bureau, New Delhi Friday, November 8, 2024, 11:35 Hrs [IST] Sanofi India has registered 46 per cent decline in ...

Among Sanofi’s rare disease drugs, new rare blood disorder drug Altuviiio, a once-weekly new class of factor VIII therapy for hemophilia A, recorded sales of €172 million in the third quarter ...

PARIS--(BUSINESS WIRE)--Regulatory News: Sanofi and Orano Med ... regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates ...

The deal would allow Sanofi to focus on its more lucrative, but riskier, innovative drugs and vaccines, and CD&R to take a 50% controlling stake in a business that is home to brands such as ...

Therefore, Sanofi's partnership with Sudair Pharma aims to address this gap and increase access to effective care for people with diabetes through insulin ... only ensuring a reliable supply of ...

The deal would allow Sanofi to focus on its more lucrative, but riskier, innovative drugs and vaccines, and CD&R to take a 50% controlling stake in a business that is home to brands such as ...

Saxenda is an older drug of the same GLP-1 drug class as the company’s popular Ozempic diabetes treatment and ... Antoine Armand wants guarantees from Sanofi that production of its popular ...